The value of clinical trials in Sweden
|Coordinator||Läkemedelsindustriföreningens Service Aktiebolag|
|Funding from Vinnova||SEK 855 000|
|Project duration||February 2018 - November 2018|
Purpose and goal
Within the project, a quantitative data collection has been conducted and analyzed to calculate the value of company-initiated clinical trials. Results in the form of quantifiable and non-quantifiable values are listed in the report.
Expected results and effects
The report shows that the quantifiable socio-economic value of an average company-initiated clinical drug trial affects GDP by 1MSEK and gives a budget effect of 0.9 MSEK. In addition, values are generated such as continuing research, knowledge dissemination, increased productivity and further research in the healthcare sector which is presented in the report.
Planned approach and implementation
The project has been carried out in collaboration with the Danish consultancy firm, Copenhagen Economics, which published a similar Danish report during 2017. In Sweden, the project has obtained advice and recommendations from a reference group. Copenhagen Economics is responsible for data collection, analysis and compilation of results including report writing. The Pharmaceutical Industry Association (LIF) has coordinated the work with the reference group, distributed surveys in connection with data collection and proofreading the draft of the report.